PB2455: THE DARK SIDE OF FECAL MICROBIOTA TRANSPLANTATION IN REFRACTORY ACUTE GASTROINTESTINAL GRAFT VERSUS HOST DISEASE.

Book Citations: Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at https://journals.lww.com/hemasphere/pages/default.aspx. Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc. 4668 least one infection during the first month following FMT. These included two cases of sepsis secondary to bacteremia caused by Veillonella Parvula and Escherichia Coli (3 and 10 days after FMT respectively); one case of endocarditis due to Staphylococcus aureus meticilino-sensible (5 days after FMT) in a patient with aortic prosthesis, a reactivation of Cytomegalovirus detected in a seropositive patient (day 30 of FMT) and one case of pneumonia (7 days after FMT) (Figure 1). To preserve the new intestinal flora, large spectrum antibiotics were only used when vital prognosis was engaged. Otherwise, none of the patients developed fungal infection during the follow up. As late gastro-intestinal complications, we noted the occurrence of a fatal occlusive syndrome and hematochezia in two patients on day 38 and 45 respectively. Cardio-vascular complications were also present, including pulmonary embolism causing death in the patient with aortic prothesis. Figure1: Scannographic image of a right superior lobal anterior sub pleural condensation Concerning response, all patients had partial response a week after FMT. Actually, the patient alive has normal stool frequency and consistency with reduction of abdominal cramps, corticosteroids and immunosuppressive medication were discontinued after a progressive tapering and close supervision. Summary/Conclusion: Fecal microbiota transplantation is becoming a growing therapy in SR GI-GvHD, the evolution of patients appears favorable and largely free of severe adverse events. However, recipients should be well aware of its potential risks. HemaSphere | 2023;7(S3) EHA2023 Hybrid Congress Copyright Information: (Online) ISSN: 2572-9241 © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. Abstract Book Citations: Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at https://journals.lww.com/hemasphere/pages/default.aspx.Book Citations: Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at https://journals.lww.com/hemasphere/pages/default.aspx. Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc. 4669